TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1875)

INSIDE INFORMATION ANNOUNCEMENT

ENTERING INTO OF AN EXCLUSIVE COMMERCIALIZATION LICENSE AND COOPERATION AGREEMENT WITH KEXING BIOPHARM IN RESPECT OF 朴欣汀® (BEVACIZUMAB INJECTION, PUSINTIN®) FOR OVERSEAS MARKETS

This announcement is made by TOT BIOPHARM International Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

EXCLUSIVE COMMERCIALIZATION LICENSE AND COOPERATION AGREEMENT FOR OVERSEAS MARKETS

The board of directors of the Company (the "**Board**") is pleased to announce that, on 11 January 2022, TOT BIOPHARM Co., Ltd. (東曜藥業有限公司) (a wholly-owned subsidiary of the Company) ("**TOT Suzhou**") entered into an exclusive commercialization license and cooperation agreement for overseas markets (the "**License and Cooperation Agreement**") with Kexing Biopharm Co., Ltd. (科興生物製藥股份有限公司) ("**Kexing Biopharm**", listed on the Shanghai Stock Exchange STAR Market (上海證券交易所科創板) (stock code: 688136)), pursuant to which Kexing Biopharm is granted an exclusive license to commercialize 朴欣汀® (bevacizumab injection, intended English trade name: Pusintin®) in all countries and regions other than China (including mainland China, Hong Kong, Macau and Taiwan regions), the European Union (based on its member states in 2021), the United Kingdom, the United States and Japan (the "**Cooperation Area**").

Pursuant to the License and Cooperation Agreement, in consideration of the grant of the exclusive commercialization license, TOT Suzhou is entitled to receive from Kexing Biopharm the following amounts:

(i) an upfront payment and research and development milestone payments of RMB30,000,000 in aggregate;

(ii) sales milestone payments up to RMB380,000,000, depending on the cumulative net sales volume of 朴欣汀® in the Cooperation Area; and

(iii) sales commissions equal to a low double-digit to high single-digit percentage (calculated on a downward sliding scale) of the cumulative net sales volume of 朴欣汀® in the Cooperation Area.

The Board is of the view that the entering into of the License and Cooperation Agreement with Kexing Biopharm is conducive to enhancing the international competitiveness of the Group's products, promoting the overseas market layout of 朴欣汀®, and providing high-quality and reasonably priced national drugs for cancer patients in emerging countries.

ABOUT TOT SUZHOU

TOT Suzhou is a limited liability company incorporated in China and is a wholly-owned subsidiary of the Company. The Company is an investment holding company incorporated in Hong Kong with limited liability, whose shares are listed on the Main Board of the Stock Exchange (stock code: 1875). The Group is principally engaged in research and development, manufacturing, and marketing of oncology drugs in China.

ABOUT KEXING BIOPHARM

With its roots tracing back to 1989, Kexing Biopharm is a scientific and innovative biopharmaceutical enterprise that focuses on the integrated research and development, production and sales of recombinant protein drugs and microecological preparation drugs in therapeutic fields including antiviral, hematology, oncology and immunity as well as digestion. Its shares are listed on the Shanghai Stock Exchange STAR Market (上海證券交易所科創板) (stock code: 688136), with its chairman Mr. Deng Xueqin (鄧學勤) as the actual controller.

To the best knowledge, information and belief of the Board having made all reasonable enquiries, Kexing Biopharm and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Listing Rules).

ABOUT 朴欣汀®

朴欣汀® (bevacizumab injection, intended English trade name: Pusintin®) is a biological antibody drug self-developed by TOT Suzhou, which has obtained the marketing approval from the National Medical Products Administration of China recently and is used for the treatment of advanced, metastatic or recurrent non-squamous non-small-cell lung cancer (nsNSCLC) and metastatic colorectal cancer (mCRC). 朴欣汀® is a biosimilar to 安維汀® (Avastin®), which has been approved for the treatment of nsNSCLC, mCRC, glioblastoma multiforme (GBM), hepatocellular carcinoma (HCC), ovarian cancer and cervical cancer in China. The monoclonal antibody commercial production of 朴欣汀® is carried out by adopting the Perfusion-Batch Hybrid Technology (PB-Hybrid® Technology) self-developed by the Group, which enables seed expansion in 25L WAVE bioreactors and a direct scale-up to 2,000L bioreactors. As compared with commonly-used technologies in the industry, this technology has obvious cost advantages in terms of simplified technical processes, shortened production cycles and reduced production costs.

By order of the Board
TOT BIOPHARM International Company Limited
Dr. Liu, Jun
Chief Executive Officer and Executive Director

Hong Kong, 11 January 2022

As at the date of this announcement, the executive Directors of the Company are Dr. Liu, Jun and Ms. Yeh-Huang, Chun-Ying; the non-executive Directors of the Company are Mr. Fu, Shan, Dr. Kung, Frank Fang-Chien, Mr. Kang, Pei and Mr. Qiu, Yu Min; and the independent non-executive Directors of the Company are Ms. Hu, Lan, Dr. Sun, Lijun Richard and Mr. Chang, Hong-Jen.